vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $62.1M, roughly 1.8× Cytek Biosciences, Inc.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs -70.9%, a 104.4% gap on every dollar of revenue. On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs 8.1%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
BY vs CTKB — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $62.1M |
| Net Profit | $37.6M | $-44.1M |
| Gross Margin | — | 52.9% |
| Operating Margin | — | -9.0% |
| Net Margin | 33.4% | -70.9% |
| Revenue YoY | 9.0% | 8.1% |
| Net Profit YoY | 33.0% | -557.1% |
| EPS (diluted) | $0.83 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $62.1M | ||
| Q3 25 | $115.7M | $52.3M | ||
| Q2 25 | $110.5M | $45.6M | ||
| Q1 25 | $103.1M | $41.5M | ||
| Q4 24 | $104.7M | $57.5M | ||
| Q3 24 | $101.8M | $51.5M | ||
| Q2 24 | $99.4M | $46.6M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $-44.1M | ||
| Q3 25 | $37.2M | $-5.5M | ||
| Q2 25 | $30.1M | $-5.6M | ||
| Q1 25 | $28.2M | $-11.4M | ||
| Q4 24 | $30.3M | $9.6M | ||
| Q3 24 | $30.3M | $941.0K | ||
| Q2 24 | $29.7M | $-10.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -9.0% | ||
| Q3 25 | 43.1% | -17.6% | ||
| Q2 25 | 35.2% | -23.3% | ||
| Q1 25 | 36.4% | -36.1% | ||
| Q4 24 | 38.6% | 5.2% | ||
| Q3 24 | 39.3% | -8.2% | ||
| Q2 24 | 40.4% | -18.3% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | -70.9% | ||
| Q3 25 | 32.1% | -10.5% | ||
| Q2 25 | 27.2% | -12.2% | ||
| Q1 25 | 27.4% | -27.5% | ||
| Q4 24 | 34.3% | 16.8% | ||
| Q3 24 | 29.8% | 1.8% | ||
| Q2 24 | 29.9% | -22.4% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | — | ||
| Q3 25 | $0.82 | — | ||
| Q2 25 | $0.66 | — | ||
| Q1 25 | $0.64 | — | ||
| Q4 24 | $0.68 | — | ||
| Q3 24 | $0.69 | — | ||
| Q2 24 | $0.68 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $90.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $341.7M |
| Total Assets | $9.9B | $461.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $90.9M | ||
| Q3 25 | $259.0M | $93.3M | ||
| Q2 25 | $218.3M | $75.5M | ||
| Q1 25 | $421.3M | $95.3M | ||
| Q4 24 | $563.1M | $98.7M | ||
| Q3 24 | $452.6M | $162.3M | ||
| Q2 24 | $730.5M | $177.9M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $341.7M | ||
| Q3 25 | $1.2B | $378.6M | ||
| Q2 25 | $1.2B | $377.6M | ||
| Q1 25 | $1.1B | $379.6M | ||
| Q4 24 | $1.1B | $395.7M | ||
| Q3 24 | $1.1B | $385.5M | ||
| Q2 24 | $1.0B | $389.1M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $461.5M | ||
| Q3 25 | $9.8B | $494.9M | ||
| Q2 25 | $9.7B | $493.3M | ||
| Q1 25 | $9.6B | $482.6M | ||
| Q4 24 | $9.5B | $499.5M | ||
| Q3 24 | $9.4B | $491.2M | ||
| Q2 24 | $9.6B | $483.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-771.0K |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -2.9% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-771.0K | ||
| Q3 25 | $38.3M | $-3.9M | ||
| Q2 25 | $16.3M | $108.0K | ||
| Q1 25 | $27.1M | $-125.0K | ||
| Q4 24 | $175.2M | $2.0M | ||
| Q3 24 | $19.8M | $13.2M | ||
| Q2 24 | $40.1M | $6.2M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $-1.8M | ||
| Q3 25 | $38.0M | $-4.6M | ||
| Q2 25 | $15.2M | $-1.5M | ||
| Q1 25 | $25.0M | $-974.0K | ||
| Q4 24 | $171.2M | $1.1M | ||
| Q3 24 | $19.1M | $12.2M | ||
| Q2 24 | $39.4M | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | -2.9% | ||
| Q3 25 | 32.8% | -8.7% | ||
| Q2 25 | 13.7% | -3.2% | ||
| Q1 25 | 24.3% | -2.3% | ||
| Q4 24 | 163.5% | 1.9% | ||
| Q3 24 | 18.8% | 23.7% | ||
| Q2 24 | 39.7% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 1.6% | ||
| Q3 25 | 0.3% | 1.3% | ||
| Q2 25 | 1.0% | 3.5% | ||
| Q1 25 | 2.0% | 2.0% | ||
| Q4 24 | 3.8% | 1.6% | ||
| Q3 24 | 0.6% | 2.0% | ||
| Q2 24 | 0.7% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | 0.21× | ||
| Q3 24 | 0.65× | 14.05× | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
